Jan 15, 2015, 00:00 AM by Michael Croft

Reuters | Genome pioneer J. Craig Venter has signed a multi-year deal to sequence and analyze tens of thousands of genomes for Roche's Genentech unit in a deal aimed at identifying new drug targets.

Jan 15, 2015, 00:00 AM by Michael Croft

Forbes | On the television newsmagazine "60 Minutes" and in a cover story for Forbes, Patrick Soon-Shiong, the world's richest doctor, has promised that his new company, NantHealth, can dramatically improve care for cancer patients everywhere. "I'm incredibly encouraged to say that we are on the path," Soon-Shiong told 60 Minutes' Sanjay Gupta. [...]

Jan 14, 2015, 12:10 PM by Michael Croft

Bio-IT World | 10X Genomics made its public debut this week at the J.P. Morgan Healthcare Conference, touting a platform that will complement Illumina's next-gen sequencers with a massively multiplexed system for reconstructing long-range genomic information.

Jan 14, 2015, 00:00 AM by Michael Croft

Forbes | This week, much of the biotech investing world is in San Francisco for the annual J.P. Morgan Healthcare Conference. Old timers like me -- I've attended nearly every year since 1998 -- remember the infinitely more manageable Hambrecht & Quist conference, still quaintly known as H&Q.

Jan 14, 2015, 00:00 AM by Michael Croft

Forbes | Moderna Therapeutics has snagged another $100m of financing, this time from Merck. A $50m cash up front payment for messenger RNA technology along with a $50m equity payment is a strong vote of confidence from the pharma in mRNA's future.

Jan 13, 2015, 12:05 PM by Michael Croft

Bio-IT World | In his address at the J.P. Morgan Healthcare Conference in San Francisco, Illumina CEO Jay Flatley announced new high-throughput instruments, a refined regulatory strategy centered on the NextSeq mid-range sequencer, and progress in oncology and prenatal testing, as his company pivots to a more hands-on approach to clinical genomics.

Jan 13, 2015, 00:00 AM by Michael Croft

STATE COLLEGE, PA, UNITED STATES - Jan 13, 2015 - . SoftGenetics announced the release of version 5.0 of its market leading software for the analysis of Sanger Sequencing

Jan 12, 2015, 13:00 PM by Michael Croft

Jan 12, 2015, 09:00 AM by Michael Croft

Jan 12, 2015, 00:00 AM by Michael Croft

Boston Business Journal | The Cambridge biotech firm, known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals.

Jan 12, 2015, 00:00 AM by Michael Croft

CALIFORNIA, CA, UNITED STATES - Jan 12, 2015 - The report firstly introduced  Prokaryotic Expression Systems Market basic information including  Prokaryotic Expression Systems Market definition, classification, application and Market chain overview;  Prokaryotic Expression Systems  Market policy and plan,  Prokaryotic Expression Systems  product specification, manufacturing process, cost structure etc

Jan 12, 2015, 00:00 AM by Michael Croft

Bloomberg | 23andMe Inc., the genetic-testing startup backed by Google Inc., is sharing DNA data on about 650,000 individuals with Pfizer Inc., to help find new targets to treat disease and to design clinical trials.

Jan 12, 2015, 00:00 AM by Michael Croft

HARDERWIJK, THE NETHERLANDS - Jan 12, 2015 - Today GENALICE and Knome, Inc. USA jointly announced a strategic partnership to offer their products together as a turn-key solution for those using next-generation sequencing (NGS) data to interpret patients' genomes

Jan 12, 2015, 00:00 AM by Michael Croft

BostonGlobe.com | These are boom times in biotechnology. Forty-one new drugs were approved for US sale in 2014, the highest tally in 18 years. A record 63 biotech startups went public, breaking the 1999 record of 52 initial public offerings. And the value of biopharma merger deals nearly tripled to $223 billion from a year earlier.

Jan 9, 2015, 14:00 PM by Michael Croft

Jan 9, 2015, 00:00 AM by Michael Croft

NEW YORK, NY, UNITED STATES - Jan 9, 2015 - CAMBRIDGE, MA, and NEW YORK, NY (January 9, 2015) - Biogen Idec (NASDAQ: BIIB) and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches

Jan 8, 2015, 10:00 AM by Michael Croft

Forbes | 2014 saw the highest number of new drug applications approved by FDA since 1996, but John LaMattina argues that the year was even more successful than that.

Jan 8, 2015, 09:00 AM by Michael Croft

New York Times | Researchers yesterday announced a new antibiotic found in dirt. Teixobactin has not been tested in humans, but was extremely effective in animal tests.

Jan 8, 2015, 00:00 AM by Michael Croft

DUBLIN, IRELAND - Jan 8, 2015 - CLIRINX Ltd. announced today that it has launched a new web-based platform for clinical research. The software allows researchers manage their studies and collect medical research data using a sophisticated, web-based system

Jan 7, 2015, 14:30 PM by Michael Croft

Bio-IT World | Novartis today became the first big pharma company to announce a CRISPR program, through a deal with Intellia Therapeutics and Caribou Biosciences that will cover CAR-T therapies and hematopoietic stem cell programs.